What is the recommended dosing, contraindications, and precautions for prescribing Avanafil to an adult male with erectile dysfunction?

Avanafil for Erectile Dysfunction: Dosing, Contraindications, and Precautions

Start with avanafil 100 mg taken orally 15 minutes before sexual activity, with the option to increase to 200 mg or decrease to 50 mg based on efficacy and tolerability; avanafil is absolutely contraindicated with any form of nitrate use. 1

FDA-Approved Dosing

• The recommended starting dose is 100 mg taken as early as 15 minutes before sexual activity. 1
• The dose may be increased to 200 mg (taken 15 minutes before activity) or decreased to 50 mg (taken 30 minutes before activity) based on individual response. 1
• Use the lowest effective dose; maximum dosing frequency is once per 24 hours. 1
• Sexual stimulation is required for avanafil to work—this is critical patient education that prevents treatment failures. 1
• Avanafil may be taken with or without food, offering flexibility compared to some other PDE5 inhibitors. 1

Absolute Contraindications

• Any form of nitrate use (sublingual nitroglycerin, long-acting nitrates, or recreational "poppers") is an absolute contraindication due to potentially fatal hypotension. 1
• If emergency nitrate administration becomes necessary after avanafil use, wait at least 12 hours after the last dose before administering nitrates under close medical supervision with hemodynamic monitoring. 1
• Known hypersensitivity to avanafil or any tablet component (hypersensitivity reactions including pruritus and eyelid swelling have been reported). 1

Critical Drug Interactions Requiring Dose Adjustment or Avoidance

Strong CYP3A4 Inhibitors

• Do not use avanafil with strong CYP3A4 inhibitors including ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, and telithromycin. 1

Moderate CYP3A4 Inhibitors

• Maximum dose is 50 mg once every 24 hours when co-administered with moderate CYP3A4 inhibitors including erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, and verapamil. 1

Alpha-Blockers

• Start avanafil at 50 mg if co-administered with an alpha-blocker, and ensure the patient is stable on alpha-blocker therapy before initiating avanafil. 1

Cardiovascular Risk Assessment Before Prescribing

• Assess whether the patient can walk 1 mile in 20 minutes or climb 2 flights of stairs in 20 seconds without symptoms—this level of exercise is equivalent to the cardiovascular demand of sexual activity. 2
• Refer to cardiology before prescribing if the patient cannot perform this level of activity or has indeterminate cardiovascular risk. 2
• Low-risk patients who can safely receive avanafil include those with asymptomatic coronary artery disease with <3 risk factors, controlled hypertension, mild stable angina, successful coronary revascularization, uncomplicated past MI, mild valvular disease, and CHF (NYHA class I). 2

Special Population Considerations

• Use with caution at lower doses initially in patients with mild to moderate hepatic or renal impairment. 2
• Men with diabetes and post-prostatectomy patients have more severe ED at baseline and may respond less robustly to avanafil, potentially requiring the 200 mg dose. 2
• Consider combining testosterone therapy with avanafil in men with both ED and testosterone deficiency, as combination therapy may improve efficacy beyond avanafil alone. 2

Efficacy Profile and Onset of Action

• Avanafil 200 mg demonstrated 64-71% successful intercourse attempts within 15 minutes of dosing compared to 27% with placebo, with efficacy maintained >6 hours post-dosing. 2
• Avanafil has similar overall efficacy to other PDE5 inhibitors in the general ED population. 2
• Treatment differences in successful sexual attempts can be demonstrated as early as 10 minutes after the 200 mg dose and 12 minutes after the 100 mg dose. 3

Common Adverse Effects

• Most common adverse events include headache, flushing, nasal congestion, nasopharyngitis, and back pain. 2
• Avanafil has the lowest rates of dyspepsia among PDE5 inhibitors and lower rates of myalgia compared to other agents (similar to tadalafil). 2
• Most adverse events are mild to moderate in severity. 4, 3, 5

Optimizing Treatment Success

• Proper patient education is essential—incorrect use accounts for many treatment failures. 2
• An adequate trial requires at least 5 separate attempts at the prescribed dose before declaring treatment failure. 2
• Ensure adequate sexual stimulation is occurring, as PDE5 inhibitors require arousal to work. 2
• Dose titration should be performed to balance efficacy and minimize adverse effects. 2
• Before switching therapies, evaluate whether the trial was adequate by addressing hormonal abnormalities, timing and frequency of dosing, adequacy of sexual stimulation, heavy alcohol use, and relationship issues. 2

Serious but Rare Adverse Events

• Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported with PDE5 inhibitors, though causality remains uncertain. 6, 2